{"transactions":[{"id":1602573,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-04T18:04:08.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.59,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001562180-24-002135","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000156218024002135/primarydocument.xml","form_type":"4"}},{"id":1877768,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-25T16:05:57.000Z","date":"2023-05-23","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.5,"value":27500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported total includes 1,292 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c)."}],"balance_after":42165,"source":{"system":"sec-edgar","filing":"0001562180-23-004477","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000156218023004477/primarydocument.xml","form_type":"4"}},{"id":2024473,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-09T16:07:56.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":135000,"derivative":{"exercise_price":7.2,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001562180-23-001168","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000156218023001168/primarydocument.xml","form_type":"4"}},{"id":2077497,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-12-22T16:05:00.000Z","date":"2022-12-21","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on December 21, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":4.9,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001562180-22-008416","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000156218022008416/primarydocument.xml","form_type":"4"}},{"id":2089422,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-12T09:13:19.000Z","date":"2022-12-08","kind":"purchase","acquired":true,"shares":10000,"price":4.76,"value":47600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported total includes 1,373 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c)."}],"balance_after":35873,"source":{"system":"sec-edgar","filing":"0001562180-22-008192","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000156218022008192/primarydocument.xml","form_type":"4"}},{"id":2249229,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-01T16:31:13.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":10000,"price":4.23,"value":42300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.22 to $4.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":24500,"source":{"system":"sec-edgar","filing":"0001562180-22-004627","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000156218022004627/primarydocument.xml","form_type":"4"}},{"id":2321007,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-22T18:01:14.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":6500,"price":7.51,"value":48815.0,"ownership":{"direct":true},"balance_after":14500,"source":{"system":"sec-edgar","filing":"0001209191-22-020585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000120919122020585/doc4.xml","form_type":"4"}},{"id":2387827,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-17T19:11:09.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":10.58,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-011037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000120919122011037/doc4.xml","form_type":"4"}},{"id":2473238,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-14T17:37:43.000Z","date":"2021-12-13","kind":"grant","acquired":true,"shares":5000,"price":12.28,"value":61400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.24 to $12.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-21-069548","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000120919121069548/doc4.xml","form_type":"4"}},{"id":2490346,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-12-01T18:00:16.000Z","date":"2021-11-29","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on November 29, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":180000,"derivative":{"exercise_price":13.75,"expiration_date":"2031-11-28","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001209191-21-067324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000120919121067324/doc4.xml","form_type":"4"}},{"id":2866147,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-11T21:28:28.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On December 18, 2019, the reporting person was granted an option to purchase 25,000 shares of AXLA common stock, subject to the satisfaction of certain performance criteria. On February 9, 2021, the Issuer's Board of Directors confirmed that the performance criteria had been met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option shall vest and become exercisable in eight equal quarterly installments, with the first installment having vested on August 31, 2020."}],"balance_after":25000,"derivative":{"exercise_price":3.4,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-020988","document":"tm216388-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465921020988/tm216388-4_4seq1.xml","form_type":"4"}},{"id":2866146,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-11T21:28:28.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest and become exercisable on February 9, 2022, with the remainder vesting in 12 equal quarterly installments thereafter."}],"balance_after":120000,"derivative":{"exercise_price":6.59,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001104659-21-020988","document":"tm216388-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465921020988/tm216388-4_4seq1.xml","form_type":"4"}},{"id":2866145,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-11T21:28:28.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of AXLA common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest as follows: 1/3 of the grant shall vest on February 9, 2023 and the remaining 2/3 of the grant shall vest on February 9, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest as follows: 1/3 of the grant shall vest on February 9, 2023 and the remaining 2/3 of the grant shall vest on February 9, 2024."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-21-020988","document":"tm216388-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465921020988/tm216388-4_4seq1.xml","form_type":"4"}},{"id":2866144,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-11T21:28:28.000Z","date":"2020-10-30","kind":"grant","acquired":true,"shares":2601,"price":3.6,"value":9363.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Axcella Health Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of May 1, 2020 to October 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on October 30, 2020."}],"balance_after":6266,"source":{"system":"sec-edgar","filing":"0001104659-21-020988","document":"tm216388-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465921020988/tm216388-4_4seq1.xml","form_type":"4"}},{"id":3296410,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-31T20:44:29.000Z","date":"2020-01-31","kind":"purchase","acquired":true,"shares":3000,"price":4.94,"value":14820.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95, inclusive. The reporting person undertakes to provide to Axcella Health Inc., any security holder of Axcella Health Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote."}],"balance_after":3665,"source":{"system":"sec-edgar","filing":"0001633070-20-000004","document":"wf-form4_158052144753507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000163307020000004/wf-form4_158052144753507.xml","form_type":"4"}},{"id":3299966,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-28T18:39:07.000Z","date":"2020-01-27","kind":"purchase","acquired":true,"shares":352,"price":4.94,"value":1738.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.94 to $4.95, inclusive. The reporting person undertakes to provide to Axcella Health Inc., any security holder of Axcella Health Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote."}],"balance_after":665,"source":{"system":"sec-edgar","filing":"0001104659-20-007760","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465920007760/a4.xml","form_type":"4"}},{"id":3299965,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-28T18:39:07.000Z","date":"2020-01-24","kind":"purchase","acquired":true,"shares":313,"price":4.92,"value":1539.96,"ownership":{"direct":true},"balance_after":313,"source":{"system":"sec-edgar","filing":"0001104659-20-007760","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465920007760/a4.xml","form_type":"4"}},{"id":3333695,"issuer":{"id":116059,"kind":"organization","name":"Axcella Health Inc.","symbol":"AXLA"},"owners":[{"id":93561,"kind":"person","name":"Chardonnet Laurent","position":1,"cik":"0001329010","reported_name":"Chardonnet Laurent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-20T20:02:07.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":72500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter."}],"balance_after":72500,"derivative":{"exercise_price":3.4,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":72500},"source":{"system":"sec-edgar","filing":"0001104659-19-075203","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329010/000110465919075203/a4.xml","form_type":"4"}}]}